

## Simplexa™ *Bordetella* New Lot and/or New Shipment Quality Control

### PURPOSE

- This procedure provides instructions for verifying reagent performance

### SAFETY CONSIDERATIONS

- Standard precautions. Refer to [MB 2.02](#) Biohazard Containment
- Use of engineering controls: Refer to [MB 3.01](#) Engineering Controls to Prevent Nucleic Acid Contamination

### ABBREVIATIONS

- BORD: *Bordetella*
- BORDP: *Bordetella* PCR
- Bp: *Bordetella pertussis*
- Bpp: *Bordetella parapertussis*
- BSC: biosafety cabinet
- Ct: crossing threshold
- F/T: freeze/thaw
- IC: internal control
- LOD: level of detection
- MM: master mix
- NEGC: negative control
- NFW: nuclease free water
- PCR: polymerase chain reaction
- PCTL: process control
- PP: primer – pair
- POSC: positive control
- PPE: personal protective equipment
- SEAC: Simplexa extraction and amplification control
- TE buffer: Tris – EDTA buffer
- Area/Room 1: Clean room
- Area/Room 2: Processing room
- Area/Room 3: Amplification room

### MATERIALS

| Equipment   | Reagents   | Supplies   |
|---|--|--|
| Room 1: Clean room <ul style="list-style-type: none"> <li>Laminar-flow hood, Clean rm 1</li> <li>Freezer, -10 to -30° C</li> <li>Refrigerator, 2 to 8° C</li> <li>Micro-centrifuge</li> <li>Nalgene cooling block</li> <li>Vortex</li> <li>Eppendorf Repeater pipette</li> <li>Dedicated set of pipettes: 2 µl, 10 µl, 20 µl, 100 µl, 200 µl, and 1000 µl pipettes</li> </ul> | TE buffer (Tris-EDTA)  | Micro tube racks   |
|   | Nuclease Free Water (NFW)  | 2 ml cryovials   |
|   | SEAC ( <i>Simplexa</i> extraction and amplification control) <ul style="list-style-type: none"> <li>Internal control primer (IC pp)</li> <li>Internal control DNA</li> </ul> | Sterile filtered pipette tips for 10 µl, 20 µl, 100 µl, 200 µl, 1000 µl pipettes |
|   | Bp Primer (Bp PP)  | Micro tubes 1.5 ml, RNase/DNase free   |
|   | Bpp Primer (Bpp PP)  | Universal disc   |
|   | <i>Bordetella</i> positive control (POSC)  | Universal disc sealer  |
|   | BORD process control (PCTL)  | Nitrile gloves (powder-free)   |
|   | TA MasterMix (TA MM)   | Sharps disposal container  |
|   | Sani-Cloth Bleach wipes  | Gripper rack, rm 2   |
|   | 70% alcohol  | Orange barrier wipes   |
| 5% Extran   | Culturette swabs   |  |
| Room 2: Processing <ul style="list-style-type: none"> <li>BSC, Process rm 2</li> <li>Refrigerator, 2 to 8° C</li> <li>Freezer, ≥ - 70°C</li> <li>Nalgene cooling block</li> <li>Vortex</li> <li>Micro-centrifuge</li> <li>Dedicated set of pipettes: 2 µl, 10 µl, 20 µl, 100 µl, 200 µl, and 1000 µl pipettes</li> <li>Gilson Concept pipette, 100 µl</li> </ul>              |  |  |
| Room 3: Amplification and detection <ul style="list-style-type: none"> <li>Liaison MDX</li> </ul>   |  |  |

**PROCEDURE A:** Follow the activities for testing reagent reactivity in the table below  
**New reagent lot and/or new shipment verification**

| Activity                                | Step                     | Action  | Related Doc   |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |
|---|--------------------------|---|---|----------------|------------------|---|--------------------------|----------|---|--------------------------|----------|---|-----------------|--|---|--------------------------|-------------------------|---|--------------------------|----------|--|
| Testing requirements                    | 1                        | Reagent components from each new lot/shipment of the BORDP assay must be tested before placing them into service for equivalent performance with the reagents currently in use. <ul style="list-style-type: none"> <li>▪ <i>B. pertussis</i> Primer-Pair</li> <li>▪ <i>B. parapertussis</i> Primer- Pair</li> <li>▪ <i>Bordetella</i> POSC</li> <li>▪ <i>Bordetella</i> PCTL</li> <li>▪ TA MM</li> <li>▪ SEAC</li> <li>▪ TE buffer</li> </ul>   | <a href="#">MB 5.02</a><br>MOLB Standards of Practice |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |
| PP, SEAC, TA MM, TE buffer verification | 2                        | Retest one known <i>B. pertussis</i> / <i>B. parapertussis</i> positive and one known negative patient sample buffer from previous lot against the new reagent lot <ul style="list-style-type: none"> <li>▪ <b>Note:</b> Select a positive sample with a Ct value between <b>30 – 32</b> to challenge the LOD and verify the sensitivity of the assay</li> </ul>  | <a href="#">MB 6.09.F1</a><br>BORDP QC worksheet      |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |
|   | 3                        | Test a PCTL, POSC and NEGC using the new lot/shipment reagents  |   |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |
| POSC verification                       | 4                        | Test the new lot POSC in parallel with the old lot POSC before placing into service   | <a href="#">MB 6.09.F2</a><br>BORDP POSC QC Worksheet |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |
| PCTL verification                       | 5                        | Test the new lot (prep date) PCTL in parallel with the old lot PCTL before placing into service   | <a href="#">MB 6.09.F3</a><br>BORDP PCTL QC Worksheet |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |
| Results                                 | 5                        | Equivalent results must be obtained <table border="1" data-bbox="456 1287 1252 1522"> <thead> <tr> <th></th> <th>Test Materials</th> <th>Expected Results</th> </tr> </thead> <tbody> <tr> <td>a</td> <td>Known positive sample/pt</td> <td>positive</td> </tr> <tr> <td>b</td> <td>Known negative sample/pt</td> <td>negative</td> </tr> <tr> <td>c</td> <td>Process Control</td> <td></td> </tr> <tr> <td>d</td> <td>Positive Reagent Control</td> <td>Positive for Bp and Bpp</td> </tr> <tr> <td>e</td> <td>Negative Reagent Control</td> <td>Negative</td> </tr> </tbody> </table> |   | Test Materials | Expected Results | a | Known positive sample/pt | positive | b | Known negative sample/pt | negative | c | Process Control |  | d | Positive Reagent Control | Positive for Bp and Bpp | e | Negative Reagent Control | Negative | New Lot/Shipment Inventory Forms <ul style="list-style-type: none"> <li>▪ <a href="#">MB 6.09.F4</a> Bp PP</li> <li>▪ <a href="#">MB 6.09.F5</a> Bpp PP</li> <li>▪ <a href="#">MB 6.09.F6</a> BORDP POSC</li> <li>▪ <a href="#">MB 8.09.F4</a> SEAC</li> <li>▪ <a href="#">MB 8.09.F5</a> TA MM</li> <li>▪ <a href="#">MB 8.09.F7</a> TE buffer</li> </ul> |
|   |                          | Test Materials  | Expected Results                                      |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |
| a                                       |                          | Known positive sample/pt  | positive  |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |
| b                                       |                          | Known negative sample/pt  | negative  |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |
| c                                       |                          | Process Control   |   |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |
| d                                       | Positive Reagent Control | Positive for Bp and Bpp   |   |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |
| e                                       | Negative Reagent Control | Negative  |   |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |
| Record                                  | 6                        | Record results on QC worksheet; staple QC worksheet to BORD segment report  |   |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |
|   | 7                        | Verify that all reagents and materials meet expiration date and QC parameters as per CLSI document MM3-A2.  |   |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |
|   | 8                        | Check off inventory form  |   |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |
|   | 9                        | Archive result forms in <i>New Lot Inventory and QC</i> manual.   |   |                |                  |   |                          |          |   |                          |          |   |                 |  |   |                          |                         |   |                          |          |  |

**PROCEDURE B:** Follow the activities for troubleshooting verification failures in the table below  
**Performance Failures**

| Activity                 | Step  | Action   | Related doc   |  |
|--------------------------|---|--|---|--|
| Troubleshooting Failures | 1   | Verify that the reagent performance is acceptable before implementation of a new lot and/or shipment | <a href="#">MB 6.05</a><br>Procedure I:<br><i>Repeat Testing</i><br><br><a href="#">MB 6.06</a><br>Simplexa<br>Troubleshooting<br>guide |  |
|                          |   | If   |   | Then   |
|                          |   | Any Control fails  |   | <ul style="list-style-type: none"> <li>Document observation/corrective action on QC log</li> <li>Do not implement new lot/shipment</li> <li>Repeat all testing; if repeat testing fails, contact DiaSorin technical service</li> </ul>   |
|                          |   | POSC fails   |   | <ul style="list-style-type: none"> <li>Amplification failure: Review amplification curve for amplification of target</li> <li>Possible reagent or system failure: Review MM preparation and assay set-up</li> <li>Repeat testing; if repeat testing fails, contact DiaSorin technical service</li> </ul> |
|                          |   | NEGC fails   |   | <ul style="list-style-type: none"> <li>Possible carryover or reagent contamination: Review pipetting technique, glove contamination, possible aerosol creation, and MM preparation</li> <li>Repeat testing; if repeat testing fails, contact DiaSorin technical service</li> </ul>                       |
|                          |   | Known pos/neg sample fails   |   | <ul style="list-style-type: none"> <li>Review amplification curve for inhibition, lost target or carryover contamination</li> <li>Select new positive sample if target appears to be lost</li> <li>Repeat testing</li> </ul>   |
| Problem unresolved       | <ul style="list-style-type: none"> <li>Call DiaSorin technical service at <b>1-800-838-4548</b>, Option #3</li> <li>Notify technical specialist/designee or technical director</li> <li>Document corrective action</li> </ul> |  |   |  |

**REFERENCES**

1. Simplexa™ 3M™ Integrated Cyclor Studio 5.0 , 3M™ Integrated Cyclor Operator Manual Reference 34-8710-8382-9, PI.MOL1101.UD\_REV. F for use with user defined assays, Focus Diagnostics 2009-2012, Focus Diagnostics, Inc. Cypress, CA
2. Clinical Verification and Validation Study performed at Children’s Hospitals and Clinics of MN August 2014
3. CLSI *Molecular Diagnostic Methods for Infectious Diseases*; Approved Guideline – Second Edition, CLSI document MM3-A2, Wayne, PA, Clinical and Laboratory Standards Institute; 2006
4. CLSI *Establishing Molecular Testing in Clinical Laboratory Environments*; Approved Guideline, MM19-A, Vol. 31. No. 21, Wayne, PA, Clinical and Laboratory Standards Institute; 2011

**Historical Record**

| Version | Written/Revised by: | Effective Date: | Summary of Revisions  |
|---------|---------------------|-----------------|---|
| 1       | P. Ackerman         | 1.23.16         | Initial Version   |
| 2       | P. Ackerman         | 07.24.16        | Reformatted for CMS upload  |
| 3       | P. Ackerman         | 03.29.17        | Instrument name change from Focus Integrated Cyclor to DiaSorin Liaison MDX; fixed hyperlinks for SharePoint upload |